Not Yet Recruiting
Belumosudil With Ruxolitnib as Second Line Therapy for Chronic Graft Versus Host Disease (cGvHD) After Steroid Failure
NCT07643025
- Conditions
- cGVHD
- Locations
-
- University Health Network Toronto, Ontario, Canada